Intravenous Fosfomycin Pharmacokinetics Study

Inclusion Criteria

• Healthy* men and women aged 18-45 years with no clinically significant findings** at Screening and Baseline (Day -1 to Day 1)

*Healthy is defined by the absence of any medical condition described in the exclusion criteria in a subject with a normal physical exam including vital signs. If the subject has another current, ongoing medical condition, the condition cannot meet any of the following criteria: 1) first diagnosed within 3 months of enrollment; 2) is worsening in terms of clinical outcome in the last 6 months; or 3) involves need for medication.

**Including findings on medical history, physical exam, vital signs, 12-lead Electrocardiogram (ECG), or clinical laboratory tests.

• Body Mass Index (BMI) = 18 - 30 kg / m^2, inclusive, and body weight > 50 kg (110 lbs).
• Females who have been surgically sterilized via bilateral oophorectomy and/or hysterectomy at least 90 days prior to Screening are considered lacking childbearing potential and will be eligible*.

*Postmenopausal females are not eligible, as the definition of menopause would require age > 45, and all subjects in this study are age 140 mmHg or diastolic pressure > 90 mmHg).

• Abnormal Electrocardiogram (ECG) at screening, as determined by the investigator to be clinically significant.
• History or presence of renal impairment or chronic renal disease.
• History or presence of liver disease (Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or total bilirubin above the upper limit of normal).
• History or presence of chronic pulmonary disease, including asthma, requiring use of medication in the year before screening.
• History of intolerance or hypersensitivity to phosphonic acid derivative antibiotics or any of its constituents (i.e., oral or intravenous fosfomycin).
• Have cancer or have a history of cancer within the past 5 years, with the exception of non-melanomatous skin cancer, treated, without evidence of recurrence.
• Any medical condition that prevents a subject from undergoing bronchoscopy with bronchoalveolar lavage (BAL).
• Serum creatinine above the upper limit of normal, or estimated creatinine clearance (CrCl) 14 drinks for males or > 7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine, or 1.5 ounces (45 mL) of 80 proof distilled spirits.
• History of > / = 10 pack-years smoking, or history of any nicotine use* in the 6 months before Baseline (Day -1 to Day 1)** or positive urinine cotinine screen at Basline (Day -1 to Day 1).

*Including cigarettes, pipe, cigar, chewing tobacco, nicotine patch.

**A positive urine cotinine at screening is allowed if negative at baseline.

• History of illicit drug use within 6 months of Baseline (Day -1 to Day 1)*.

*Use of cannabinoids within 1 month of Baseline (Day -1 to Day 1) is excluded, but other use of cannabinoids within 6 months is permitted.

• Use of any prescription drugs, except acceptable contraception methods listed above, within 30 days of Baseline (Day -1 to Day 1).
• Involvement in other investigational studies of any type (drugs, devices, procedures) within 30 days of Baseline (Day -1 to Day 1).
• Blood or blood products donation within 30 days of Baseline (Day -1 to Day 1).
• Planning egg or sperm donation any time before Day 3 follow-up call.
• Use of any non-prescription medications, vitamins, consumption > 2 times/week of products containing genuine licorice, caffeine, or dietary or herbal supplements within 7 days of Baseline (Day -1 to Day 1)*.

*Excluded from this list is intermittent use of acetaminophen at doses 37.8 degrees Celsius (> 100.0 degrees Fahrenheit), within 7 days of Baseline (Day -1 to Day 1).

• Currently pregnant or breastfeeding as determined by subject report.
• Positive tests for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody.
• Positive urine drug